National Institute of Allergy and Infectious Diseases (NIAID)
Also known as: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Autoimmunity Centers of Excellence | Autoimmunity Centers of Excellence (ACE) | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) | Division of AIDS, US National Institute of Allergy and Infectious Diseases | Koneti Rao | National Institute of Allergy and Infectious Disease (NIAID) | National Institute of Allergy and Infectious Diseases (NIAID) | National Institute of Allergy and Infectious Diseases (NIAID)/Division of AIDS (DAIDS) | Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Highest phase reached
Phase 4
First clinical trial
Feb 1, 1976Last known activity
Mar 2, 2026
Timeline
1950s
- Dec 29, 1955
National Institute of Allergy and Infectious Diseases (NIAID)— Founded
Drugs by trial phase (1160 distinct, 2279 trials)
Phase 4 (139 own, 0 via acquisition)
Phase 3 (136 own, 0 via acquisition)
Phase 2 (390 own, 0 via acquisition)
Phase 1 (466 own, 0 via acquisition)
Indications
Studied for
- Acanthocheilonemiasis
- Acquired Immunodeficiency Syndrome
- Acute Lung Injury
- Adenoviridae Infections
- Agammaglobulinemia
- AIDS-Associated Nephropathy
- AIDS Dementia Complex
- AIDS-Related Complex
- AIDS-Related Opportunistic Infections
- Alphavirus Infections
- Amebiasis
- Anaphylaxis
- Ancylostomiasis
- Anemia, Sickle Cell
- Angioedema
- Anthrax
- Anus Neoplasms
- Arachnodactyly
- Arteritis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Aspergillosis
- Asthma
- Autoimmune Diseases
- Autoimmune Lymphoproliferative Syndrome
- Bacterial Infections
- beta-Thalassemia
- Blastomycosis
- Bone Diseases, Metabolic
- Botulism
- Brain Diseases
- Bronchial Spasm
- Bronchiectasis
- Cachexia
- Candidiasis
- Candidiasis, Chronic Mucocutaneous
- Candidiasis, Oral
- Candidiasis, Vulvovaginal
- Cardiovascular Diseases
- Celiac Disease
- Cellulitis
- Central Nervous System Diseases
- Cervical Intraepithelial Neoplasia
- Chagas Disease
- Chickenpox
- Chikungunya Fever
- Chlamydia Infections
- Chorioamnionitis
- Churg-Strauss Syndrome
- Clostridium Infections
- Coccidioidomycosis
- Coccidiosis
- Cognition Disorders
- Coinfection
- Colitis
- Colitis, Ulcerative
- Common Variable Immunodeficiency
- Communicable Diseases
- Congenital Abnormalities
- Coronavirus Infections
- Craniosynostoses
- Critical Illness
- Crohn Disease
- Cryptococcosis
- Cryptosporidiosis
- Cysticercosis
- Cytomegalovirus Infections
- Cytomegalovirus Retinitis
- Dementia
- Dengue
- Dermatitis
- Dermatitis, Atopic
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diarrhea
- DiGeorge Syndrome
- Digestive System Diseases
- Dipetalonema Infections
- Diphtheria
- Disease Progression
- Disease Susceptibility
- Dysbiosis
- Dysentery
- Dysentery, Amebic
- Dysentery, Bacillary
- Eczema
- Egg Hypersensitivity
- Elephantiasis
- Elephantiasis, Filarial
- Emergencies
- Encephalitis
- Encephalitis, Herpes Simplex
- Encephalitis, Tick-Borne
- Encephalomyelitis, Eastern Equine
- Encephalomyelitis, Equine
- Encephalomyelitis, Venezuelan Equine
- Encephalomyelitis, Western Equine
- Endotoxemia
- Eosinophilia
Recent trials (50)
- NCT00000774Lead sponsorPhase 1—
- NCT07215858OfficialPhase 2Mar 2, 2026
- NCT07215858Lead sponsorPhase 2Mar 2, 2026
- NCT07015996Lead sponsorPhase 2Feb 18, 2026
- NCT06987318Lead sponsorPhase 1Feb 15, 2026
- NCT07059091CollaboratorPhase 2Jan 31, 2026
- NCT06856174CollaboratorPhase 4Jan 19, 2026
- NCT06856174Lead sponsorPhase 4Jan 19, 2026
- NCT07216794Lead sponsorPhase 2Jan 17, 2026
- NCT07076862CollaboratorEarly Phase 1Dec 31, 2025
- NCT07108387Lead sponsorPhase 2Dec 15, 2025
- NCT07124559Lead sponsorPhase 1/Phase 2Dec 15, 2025
- NCT07262983Lead sponsorPhase 1Dec 14, 2025
- NCT07262983OfficialPhase 1Dec 14, 2025
- NCT07215871OfficialPhase 1Dec 2, 2025
Details
- Founded
- Bethesda, MD, US Dec 29, 1955
- Last known activity
- Mar 2, 2026